循环 microRNA miR-21-5p、miR-150-5p 和 miR-30e-5p 与迟发性重症肌无力的临床状态相关。
Circulating microRNA miR-21-5p, miR-150-5p and miR-30e-5p correlate with clinical status in late onset myasthenia gravis.
机构信息
Department of Neuroscience, Clinical Neurophysiology, Uppsala University, Uppsala, Sweden.
Department of Neurology, Nottingham University, Hospitals NHS Trust, Queens Medical Centre, Nottingham, Nottinghamshire, UK.
出版信息
J Neuroimmunol. 2018 Aug 15;321:164-170. doi: 10.1016/j.jneuroim.2018.05.003. Epub 2018 May 8.
There are no biomarkers for late onset myasthenia gravis (LOMG; onset >50 years). We evaluated circulating microRNA in a discovery cohort of 4 LOMG patients and 4 healthy controls and in a prospective diagnostic validation cohort of 73 LOMG patients (48 male) with longitudinal follow-up samples. In immunosuppression naïve patients, levels of miRNAs miR-150-5p, miR-21-5p and miR-30e-5p decreased in parallel with clinical improvement after initiation of immunosuppression and their levels positively correlated with the clinical MG composite score. Levels of miR-150-5p and miR-21-5p were lower in patients with ocular compared to generalized LOMG. Circulating miR-150-5p, miR-21-5p and miR-30e-5p correlate with the clinical course in LOMG.
尚无迟发性重症肌无力 (LOMG; 发病年龄 >50 岁) 的生物标志物。我们在一个包含 4 名 LOMG 患者和 4 名健康对照的发现队列中评估了循环 microRNA，并在一个包含 73 名 LOMG 患者（48 名男性）的前瞻性诊断验证队列中进行了纵向随访样本评估。在免疫抑制初治患者中，miR-150-5p、miR-21-5p 和 miR-30e-5p 的水平在开始免疫抑制后与临床改善平行下降，其水平与临床 MG 综合评分呈正相关。与全身性 LOMG 相比，眼部 LOMG 患者的 miR-150-5p 和 miR-21-5p 水平较低。循环 miR-150-5p、miR-21-5p 和 miR-30e-5p 与 LOMG 的临床病程相关。
Zotero 插件